Zalicus Publishes Data on Selective Estrogen Receptor Modulators for the Treatment of Infectious Disease

  Zalicus Publishes Data on Selective Estrogen Receptor Modulators for the
  Treatment of Infectious Disease

   Results in Science Translational Medicine Highlight the Benefits of the
 Zalicus Combination High-throughput Screening (cHTS) Technology to Identify
                  Novel Treatments for Ebolavirus Infections

Business Wire

CAMBRIDGE, Mass. -- June 19, 2013

Zalicus Inc. (Nasdaq Capital Market: ZLCS) today announced that it has
published preclinical data in Science Translational Medicine showing the
beneficial effects of applying the Zalicus combination high-throughput
screening (cHTS) technology for the potential treatment of ebolavirus (EBOV)
infections. In the paper entitled “FDA-Approved Selective Estrogen Receptor
Modulators Inhibit Ebola Virus Infection,” the scientists, including drug
developers from Zalicus and collaborators from the U.S. Army Medical Research
Institute of Infectious Diseases (USAMRIID) and investigators from the
University of Virginia School of Medicine (UVA), describe screening a series
of approved drugs and select molecular probes to identify drugs with
antifilovirus activity.

“These data continue to confirm the potential of our combination
high-throughput screening technology to identify drug combinations with
activity in multiple disease states. The value of our cHTS technology, which
has been previously validated in a number of cancer indications, continues to
demonstrate promise in infectious disease applications as well,” commented
Mark H.N. Corrigan, MD, President and CEO of Zalicus. “Our cHTS discovery
collaborations with USAMRIID and UVA and pharmaceutical companies such as
Novartis validate the value of the cHTS discovery technology to identify novel
treatments for diseases.”

Key findings include:

  *Identified a set of selective estrogen receptor modulators (SERMs),
    including clomiphene and toremifene, which act as potent inhibitors of
    EBOV infection.
  *Confirmed Anti-EBOV activity for both SERMs in an in vivo mouse infection
  *The SERM compounds inhibit viral entry and are not working through
    classical estrogen receptor-associated pathways.
  *These data support the screening of readily available approved drugs to
    identify therapeutics for the ebolaviruses and other biothreat infectious

About Zalicus

Zalicus Inc. (Nasdaq Capital Market: ZLCS) is a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from pain.
Zalicus has a portfolio of proprietary clinical-stage product candidates
targeting pain such as Z160 and Z944 and has entered into multiple
revenue-generating collaborations with large pharmaceutical companies relating
to other products, product candidates and drug discovery technologies. Zalicus
applies its expertise in the discovery and development of selective ion
channel modulators and its combination high throughput screening capabilities
to discover innovative therapeutics for itself and its collaborators in the
areas of pain, inflammation, oncology and infectious disease. To learn more
about Zalicus, please visit


USAMRIID’s mission is to protect the warfighter from biological threats and to
be prepared to investigate disease outbreaks or threats to public health.
Research conducted at USAMRIID leads to medical solutions—vaccines, drugs,
diagnostics, and information—that benefit both military personnel and
civilians. The Institute plays a key role as the lead military medical
research laboratory for the Defense Threat Reduction Agency’s Joint Science
and Technology Office for Chemical and Biological Defense. USAMRIID is a
subordinate laboratory of the U.S. Army Medical Research and Materiel Command.
The information contained in this press release does not necessarily reflect
the position or the policy of the Government and no official endorsement
should be inferred.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 concerning Zalicus, its
cHTS discovery technology and its potential and its other business plans.
These forward-looking statements about future expectations, plans, objectives
and prospects of Zalicus and its product candidates may be identified by words
like "believe," "expect," "may," "will," "should," "seek," “plan” or “could”
and similar expressions and involve significant risks, uncertainties and
assumptions, including risks related to the unproven nature of the Zalicus
drug discovery technologies, the Company's ability to obtain additional
financing or funding for its research and development, and those other risks
that can be found in the "Risk Factors" section of Zalicus' annual report on
Form 10-K on file with the Securities and Exchange Commission and the other
reports that Zalicus periodically files with the Securities and Exchange
Commission. Actual results may differ materially from those Zalicus
contemplated by these forward-looking statements. These forward-looking
statements reflect management’s current views and Zalicus does not undertake
to update any of these forward-looking statements to reflect a change in its
views or events or circumstances that occur after the date of this release
except as required by law.

(c) 2013 Zalicus Inc. All rights reserved.


Zalicus Inc.
Justin Renz, CFO, 617-301-7575
Gina Nugent, 617-460-3579
Press spacebar to pause and continue. Press esc to stop.